Teva Pharmaceutical Industries Limited (TEVA) Upgraded to Sell by BidaskClub

Teva Pharmaceutical Industries Limited (NYSE:TEVA) was upgraded by equities research analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research note issued to investors on Wednesday.

Several other equities analysts have also issued reports on the company. Vetr raised Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating and set a $34.17 price target on the stock in a research note on Monday, July 24th. Credit Suisse Group lowered Teva Pharmaceutical Industries Limited from a “neutral” rating to an “underperform” rating and dropped their price target for the company from $25.00 to $13.00 in a research note on Wednesday, August 23rd. TheStreet lowered Teva Pharmaceutical Industries Limited from a “c-” rating to a “d+” rating in a research note on Friday, August 25th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $37.00 target price (down from $38.00) on shares of Teva Pharmaceutical Industries Limited in a research report on Monday, July 17th. Finally, Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and set a $21.00 target price (down from $28.00) on shares of Teva Pharmaceutical Industries Limited in a research report on Thursday, August 31st. Five analysts have rated the stock with a sell rating, nineteen have given a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. Teva Pharmaceutical Industries Limited presently has an average rating of “Hold” and a consensus target price of $32.65.

Shares of Teva Pharmaceutical Industries Limited (NYSE TEVA) opened at 19.33 on Wednesday. The company’s market capitalization is $19.64 billion. Teva Pharmaceutical Industries Limited has a 1-year low of $15.22 and a 1-year high of $52.66. The company’s 50-day moving average price is $20.60 and its 200-day moving average price is $28.94.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its quarterly earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.06 by ($0.07). Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The business had revenue of $5.69 billion during the quarter, compared to analyst estimates of $5.72 billion. During the same period last year, the firm posted $1.25 earnings per share. Teva Pharmaceutical Industries Limited’s quarterly revenue was up 12.9% compared to the same quarter last year. On average, equities analysts expect that Teva Pharmaceutical Industries Limited will post $4.32 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Teva Pharmaceutical Industries Limited (TEVA) Upgraded to Sell by BidaskClub” was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece on another site, it was illegally copied and republished in violation of United States and international copyright & trademark law. The correct version of this piece can be viewed at https://sportsperspectives.com/2017/09/13/teva-pharmaceutical-industries-limited-teva-upgraded-to-sell-by-bidaskclub.html.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Sii Investments Inc. WI lifted its position in shares of Teva Pharmaceutical Industries Limited by 0.4% during the 1st quarter. Sii Investments Inc. WI now owns 6,739 shares of the company’s stock valued at $214,000 after buying an additional 25 shares during the last quarter. Salem Investment Counselors Inc. lifted its position in shares of Teva Pharmaceutical Industries Limited by 0.4% during the 1st quarter. Salem Investment Counselors Inc. now owns 8,332 shares of the company’s stock valued at $267,000 after buying an additional 32 shares during the last quarter. Security National Bank of Sioux City Iowa IA lifted its position in shares of Teva Pharmaceutical Industries Limited by 0.4% during the 2nd quarter. Security National Bank of Sioux City Iowa IA now owns 21,788 shares of the company’s stock valued at $724,000 after buying an additional 87 shares during the last quarter. Bronfman E.L. Rothschild L.P. lifted its position in shares of Teva Pharmaceutical Industries Limited by 2.6% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock valued at $123,000 after buying an additional 94 shares during the last quarter. Finally, Sterling Investment Advisors Ltd. lifted its position in shares of Teva Pharmaceutical Industries Limited by 2.6% during the 1st quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock valued at $125,000 after buying an additional 100 shares during the last quarter. 56.87% of the stock is currently owned by hedge funds and other institutional investors.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply